| | | | |
p Values
|
|---|
| |
Early recurrence (n = 184)
|
Late recurrence (n = 134)
|
No recurrence (n = 321)
|
Early vs no recurrence
|
Late vs no recurrence
|
Early vs late recurrence
|
|---|
|
Age, years
| | | | | | |
|
≤ 50
|
82 (44.57)
|
49 (36.57)
|
120 (37.38)
|
0.113
|
0.869
|
0.151
|
|
> 50
|
102 (55.43)
|
85 (63.43)
|
201 (62.62)
| | | |
|
Menopausal status
| | | | | | |
|
Postmenopausal
|
90 (48.91)
|
81 (60.45)
|
171 (53.27)
|
0.345
|
0.159
|
0.041
|
|
Premenopausal
|
94 (51.09)
|
53 (39.55)
|
150 (46.73)
| | | |
|
Bilateral breast cancer
| | | | | | |
|
Absent
|
169 (91.85)
|
121 (90.30)
|
319 (99.38)
|
<0.001
|
<0.001
|
0.631
|
|
Present
|
15 (8.15)
|
13 (9.70)
|
2 (0.62)
| | | |
|
Tumor size, mm
| | | | | | |
|
≤ 20
|
49 (26.63)
|
44 (32.84)
|
187 (58.26)
|
<0.001
|
<0.001
|
0.23
|
|
> 20
|
135 (73.37)
|
90 (67.16)
|
134 (41.74)
| | | |
|
Nodal metastasis
| | | | | | |
|
Negative
|
93 (50.54)
|
79 (58.96)
|
267 (83.18)
|
<0.001
|
<0.001
|
0.136
|
|
Positive
|
91 (49.46)
|
55 (41.04)
|
54 (16.82)
| | | |
|
Histological type
| | | | | | |
|
IDC-NST
|
171 (92.93)
|
124 (92.54)
|
297 (92.52)
|
0.864
|
0.995
|
0.892
|
|
Others
|
13 (7.07)
|
10 (7.46)
|
24 (7.48)
| | | |
|
Estrogen receptor staining
| | | | | | |
|
< 10 %
|
16 (8.70)
|
10 (7.46)
|
27 (8.41)
|
0.396
|
0.367
|
0.915
|
|
10–50 %
|
57 (30.98)
|
43 (32.09)
|
82 (25.55)
| | | |
|
≥ 50 %
|
111 (60.33)
|
81 (60.45)
|
212 (66.04)
| | | |
|
Progesterone receptor staining
| | | | | | |
|
≤ 20 %
|
85 (46.20)
|
59 (44.03)
|
133 (41.43)
|
0.298
|
0.609
|
0.701
|
|
> 20 %
|
99 (53.80)
|
75 (55.97)
|
188 (58.57)
| | | |
|
Tumor grade
| | | | | | |
|
1 or 2
|
131 (71.20)
|
106 (79.10)
|
278 (86.60)
|
<0.001
|
0.049
|
0.107
|
|
3
|
53 (28.80)
|
28 (20.90)
|
43 (13.40)
| | | |
|
Ki-67 staining
| | | | | | |
|
≤ 20 %
|
136 (73.91)
|
114 (85.07)
|
265 82.55)
|
0.022
|
0.507
|
0.014
|
|
> 20 %
|
48 (26.09)
|
20 (14.93)
|
56 (17.45)
| | | |
|
Local recurrence
| | | | | | |
|
Absent
|
136 (78.61)
|
96 (71.64)
|
0
| | | |
|
Present
|
37 (21.39)
|
38 (28.36)
|
0
| | | |
|
Surgical treatment
| | | | | | |
|
Total mastectomy
|
117 (63.59)
|
78 (58.21)
|
106 (33.02)
|
0.076
|
<0.001
|
0.331
|
|
Partial mastectomy
|
67 (36.41)
|
56 (41.79)
|
215 (66.98)
| | | |
|
Radiation therapy
| | | | | | |
|
Absent
|
100 (54.35)
|
92 (68.66)
|
149 (46.42)
|
<0.001
|
<0.001
|
0.009
|
|
Present
|
84 (45.65)
|
42 (31.34)
|
172 (53.58)
| | | |
|
Adjuvant treatment
| | | | | | |
|
None
|
13 (7.07)
|
4 (2.99)
|
30 (9.35)
|
<0.001
|
<0.001
|
0.021
|
|
Chemotherapy only
|
19 (10.33)
|
6 (4.48)
|
7 (2.18)
| | | |
|
Endocrine therapy only
|
53 (28.80)
|
55 (41.04)
|
180 (56.07)
| | | |
|
Combined therapy
|
99 (53.80)
|
69 (51.49)
|
104 (32.40)
| | | |
|
Neoadjuvant chemotherapy
| | | | | | |
|
Absent
|
168 (91.30)
|
131 (97.76)
|
305 (95.31)
|
0.076
|
0.198
|
0.011
|
|
Present
|
16 (8.70)
|
3 (2.24)
|
15 (4.69)
| | | |
|
Chemotherapy
| | | | | | |
|
A + T
|
54 (29.35)
|
22 (16.42)
|
42 (13.08)
| | | |
|
A
|
39 (21.20)
|
31 (23.13)
|
40 (12.46)
| | | |
|
T
|
6 (3.26)
|
7 (5.22)
|
13 (4.05)
| | | |
|
CMF
|
17 (9.24)
|
12 (8.96)
|
13 (4.05)
| | | |
|
Other
|
2 (1.09)
|
3 (2.24)
|
3 (0.93)
| | | |
|
None
|
66 (35.87)
|
59 (44.03)
|
210 (65.42)
| | | |
|
Endocrine therapy
| | | | | | |
|
TAM
|
61 (33.15)
|
34 (25.37)
|
68 (21.18)
| | | |
|
TAM + LHRH
|
30 (16.30)
|
18 (13.43)
|
35 (10.90)
| | | |
|
TAM → AI
|
16 (8.70)
|
36 (26.87)
|
72 (22.43)
| | | |
|
TAM + LHRH → AI
|
1 (0.54)
|
3 (2.24)
|
15 (4.67)
| | | |
|
AI
|
39 (21.20)
|
27 (20.15)
|
87 (27.10)
| | | |
|
LHRH
|
5 (2.72)
|
6 (4.48)
|
7 (2.18)
| | | |
|
None
|
32 (17.39)
|
10 (7.46)
|
37 (11.53)
| | |
-
Abbreviations: IDC-NST invasive ductal carcinoma of no special type, A + T anthracycline and taxane, A anthracycline, T taxane, CMF cyclophosphamide, methotrexate, and fluorouracil, TAM tamoxifen, TAM + LHRH tamoxifen and luteinizing hormone-releasing hormone, TAM → AI tamoxifen followed by aromatase inhibitor, TAM + LHRH → AI tamoxifen and luteinizing hormone-releasing hormone followed by aromatase inhibitor, AI aromatase inhibitor, LHRH luteinizing hormone-releasing hormone
